During the past decade, Universitätsklinik für Innere Medizin conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 4 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinik für Innere Medizin" #1 sponsor was "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 5 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Astellas Pharma Inc" with 2 trials sponsored, "University of Wuerzburg" with 2 trials sponsored and "Cornerstone Pharmaceuticals" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinik für Innere Medizin" #1 collaborator was "Amgen" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Roche Pharma AG" with 2 trials as a collaborator, "Assign Data Management and Biostatistics GmbH" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinik für Innere Medizin" are "Multiple Myeloma" (4 trials), "Breast Cancer" (2 trials), "Acute Myeloid Leukemia" (1 trials), "Aspergillosis" (1 trials) and "B-cell Lymphoma" (1 trials). Many other conditions were trialed in "Universitätsklinik für Innere Medizin" in a lesser frequency.

Most popular intervention types in "Universitätsklinik für Innere Medizin" are "Drug" (14 trials), "Other" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "FK463" (2 trials), "5-Fluorouracil" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody" (1 trials) and "Belimumab 1 mg/kg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinik für Innere Medizin" are 17 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Universitätsklinik für Innere Medizin". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Universitätsklinik für Innere Medizin, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinik für Innere Medizin, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".